Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biopharmaceutical classification

Executive Summary

Final FDA guidance should issue in the next few weeks, Office of Pharmaceutical Science Acting Director Helen Winkle said May 15 at the National Association of Pharmaceutical Manufacturers mid-year meeting in Newark, N.J. Center for Drug Evaluation & Research Director Janet Woodcock, MD, "has already signed the guidance," Winkle said. A training session will be held June 19. The draft was published in February 1999 (1"The Pink Sheet" Feb. 22, 1999, p. 24)

You may also be interested in...

Biowaivers Proposed For Highly Permeable, Soluble, Rapidly Dissolving Drugs

FDA is proposing to grant waivers of in vivo bioequivalence tests for certain immediate-release solid oral dosage form drugs that meet the characteristics of being highly permeable, soluble and having rapid dissolution.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts